Solution Structure of Poly(ethylene) Glycol-Conjugated Hemoglobin Revealed by Small-Angle X-Ray Scattering: Implications for a New Oxygen Therapeutic  by Svergun, Dmitri I. et al.
Solution Structure of Poly(ethylene) Glycol-Conjugated Hemoglobin
Revealed by Small-Angle X-Ray Scattering: Implications for a New
Oxygen Therapeutic
Dmitri I. Svergun,*y Fredrik Ekstro¨m,z Kim D. Vandegriff,§ Ashok Malavalli,§ Dale A. Baker,§{ Calle Nilsson,z
and Robert M. Winslow§{
*European Molecular Biology Laboratory, Hamburg Outstation, Hamburg, Germany; yInstitute of Crystallography, Russian Academy of
Sciences, Moscow, Russia; zSwedish Defense Research Agency (FOI), CBRN Defense and Security, Umea˚, Sweden; §Sangart Inc.,
San Diego, California; and {Department of Bioengineering, University of California, San Diego, California
ABSTRACT Developing protein therapeutics has posed challenges due to short circulating times and toxicities. Recent ad-
vances using poly(ethylene) glycol (PEG) conjugation have improved their performance. A PEG-conjugated hemoglobin (Hb),
Hemospan, is in clinical trials as an oxygen therapeutic. Solutions of PEG-hemoglobin with two (P5K2) or six to seven strands of
5-kD PEG (P5K6) were studied by small-angle x-ray scattering. PEGylation elongates the dimensions (Hb, P5K2, P5K6) and
leaves the tertiary hemoglobin structure unchanged but compacts its quaternary structure. The major part of the PEG chains
visualized by ab initio reconstruction protrudes away from hemoglobin, whereas the rest interacts with the protein. PEGylation
introduces intermolecular repulsion, increasing with conjugated PEG amount. These results demonstrate how PEG surface
shielding and intermolecular repulsion may prolong intravascular retention and lack of reactivity of PEG-Hb, possibly by inhibiting
binding to themacrophage CD163 hemoglobin-scavenger receptor. The proposedmethodology for assessment of low-resolution
structures and interactions is a powerful means for rational design of PEGylated therapeutic agents.
INTRODUCTION
Poly(ethylene) glycol (PEG) is an inert, synthetic polymer
increasingly being used to modify drugs and proteins to
enhance stability and retention time and lower toxicity (1,2).
For example, covalent attachments of PEG to the surfaces of
acetylcholinesterase or interferon-b-1b increase their circu-
latory residency times (3,4). In parallel, PEG-conjugated
hemoglobin (Hb) is being explored for use as a hemoglobin-
based oxygen carrier (HBOC). Hemospan is human oxyHb
conjugated to an average of six to seven PEGs (5-kD) per Hb
tetramer. This product, also referred to in the literature asMP4,
is formulated at;4 g/dl and has been the subject of biochem-
ical (5–8) and physiologic investigations that have shown it to
be a safe and effective oxygen-transport agent in animalmodels
of hemodilution (9,10) andhemorrhage (11,12).Hemospanhas
successfully completed Phase I (13) and Phase II clinical trials
(14), with Phase III trials underway in Europe.
Despite ongoing development of several therapeutic PEG-
conjugated proteins, including Hb, the effect of the PEG
polymer on the three-dimensional (3D) structure of proteins is
poorly understood. The relatively large, highly ﬂexible PEG-
polymer conjugates impede crystallization and structural
determination by protein crystallography. Thus, considering
the substantial amount of biochemical and structural data on
Hb, the corresponding PEG-conjugated Hb (PEG-Hb) pro-
vides an excellent model to study the general architecture of
the PEG envelope and its impact on the 3D structure of the
conjugated protein. Accordingly, in this study, we present
small angle x-ray scattering (SAXS) solution structures of Hb
conjugated to 5-kDmaleimide-activated PEG (MalPEG)with
either two (P5K2) or an average of six to seven (P5K6) PEGs
attached per Hb tetramer. In the case of P5K2, the MalPEGs
are conjugated at the two free thiols of Cys-b93, whereas in
P5K6, additional MalPEGs are conjugated after reaction at
surface-exposed lysines with 2-iminothiolane (Fig. 1).
MATERIALS AND METHODS
Sample preparation
Hb and P5K6 were prepared as described previously for Hb and P5K6,
respectively (5). Another PEG-Hb derivative, P5K2, with two PEGs at-
tached per tetramer was prepared by the same method described for P5K6,
except that no thiolation was performed before the reaction with PEG; in this
case, the maleimide-PEG reacts only at the two Cys-b93 residues. Reagents
and enzymes of the highest purity available were obtained from Sigma
Chemicals (St. Louis, MO). Maleimide-activated PEG was provided by
NOF (Tokyo, Japan).
SAXS analysis
All samples were equilibrated in Ringer’s lactate buffer. Synchrotron radia-
tion scattering data were collected on the X33 beamline of the European
Molecular Biology Laboratory, Hamburg Outstation (DORIS III storage
ring, DESY) (15). The sample-detector distance was 2.5 m with the wave-
length l¼ 1.5 A˚ covering the momentum transfer range 0.01, s, 0.5 A˚1
(here, s¼ 4p sin(u)/lwhere 2u is the scattering angle). Solutions of free and
PEGylated Hbs were measured on a MAR345 image plate detector for at
least four solute concentrations, each ranging from 2.5 to 31.5 mg/ml. The
exposure time was 3 min; to check for radiation damage, two successive
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2-min exposures were compared, and no radiation-induced effects were
observed. The data were processed and extrapolated to zero-solute concen-
tration, following standard procedures using the program package PRIMUS
(16). The forward scattering I(0) and the radius of gyration Rg were cal-
culated by Guinier plot (17). The distance distribution functions and the
maximum particle dimension Dmax were evaluated using the program
GNOM (18). The molecular masses (MM) of the solutes were estimated by
comparison of the I(0) values with that from a reference solution of bovine
serum albumin. For the PEG-containing constructs, this calibration was
corrected by the difference in the partial speciﬁc volumes of Hb (taken as
0.74 cm3/g (19)) and PEG (taken as 0.83 cm3/g (20)). The volumes occupied
by the hydrated particles in solution were computed using the Porod
invariant (21). The scattering from the atomic models of Hb was calculated
using the program CRYSOL (22).
Low-resolution 3D models of Hb, P5K2, and P5K6 were computed ab
initio by the program GASBOR (23), which represents a protein by an
assembly of dummy residues (DRs) within the search volume with diameter
Dmax to ﬁt the experimental scattering data Iexp(s) by minimizing discrepancy:
x
2 ¼ 1
N  1+j
IexpðsjÞ  cIcalcðsjÞ
sðsjÞ
 2
; (1)
where N is the number of experimental points, c is a scaling factor, and
Icalc(sj) and s(sj) are the calculated intensity and the experimental error at the
momentum transfer sj, respectively. GASBOR was originally designed for
proteins, but it also can be applicable for the PEG chains. The density of
PEG5000 is ;1.2 g/cm3 (20), i.e., its electron density (;0.4 e/A˚3) is not
signiﬁcantly different from that of Hb (;0.43 e/A˚3). The models of Hb were
built from 574 residues, as in its sequence. For P5K2 and P5K6, 664 and 842
residues were used, respectively, to account for the extra MM (10 and 30
kDa, respectively) of PEG chains in these constructs. The overall shapes of
the PEGylated models were not sensitive to 65% alterations of the number
of residues in the model. The shapes of the DR models were aligned to the
crystal structure of the most recently reﬁned model of oxyHb (Protein Data
Bank (PDB) entry code 2DN1) using the program Supcomb (24).
In an alternative approach, an ab initio model highlighting Hb and PEG
moieties was generated by a multiphase bead modeling program MONSA
(25,26). This program describes the model by an assembly of small beads
densely packed with packing radius 2.5 A˚ inside a spherical search volume
with Dmax ¼ 130 A˚ as for P5K6. The beads may belong either to solvent or
to any of three phases (structural components): i), Hb, ii), two PEG chains in
P5K2; iii), the remaining PEG chains in P5K6. This model accounts for the
difference between the contrasts of Hb and PEG (the latter is taken to be 0.80
of the former). Starting from a random assignment of the phases, simulated
annealing was employed to ﬁnd which bead belongs to which phase by
simultaneous ﬁtting of the three scattering curves from Hb, P5K2, and P5K6.
Before the MONSA ﬁtting, appropriate constants were subtracted from each
data point of these scattering curves to force the s4 decay of the intensity at
higher angles, following the Porod’s law for homogeneous particles (21) as
required for the bead modeling assuming uniform density inside each phase.
Subject to this uniformity requirement, a limited portion of the scattering
data up to s¼ 0.37 A˚1 (resolution of;17 A˚) was accounted for in MONSA
analysis.
Both GASBOR andMONSAwere run without symmetry constraints and
using P222 symmetry restrictions, and these runs yielded similarly elongated
models for the PEGylated Hb. In symmetric runs, the PEG chains protruded
toward both sides of Hb (see Figs. 4 and 5), whereas in asymmetric runs
models could be also obtained where the PEG chains protruded toward one
side of Hb (data not shown). The asymmetric models showed otherwise
similar arrangement of PEG chains with respect to Hb, and this ambiguity
does not inﬂuence the conclusions of the article. Given the isotropic en-
vironment of Hb in solution, symmetric models presented in Figs. 4 and 5
appear to be much more plausible (although the presence of asymmetric
shapes or a mixture of symmetric and asymmetric shapes cannot be excluded
based in the SAXS data).
RESULTS
Overall parameters from SAXS
The processed scattering patterns from PEGylated Hb reveal
strong repulsive interactions between particles in solution,
which manifest as interference peaks at small angles in
solutions at higher solute concentration. This is illustrated in
Fig. 2 A, comparing Hb and P5K6 data recorded at low and
high solute concentrations. The structure factors of Hb,
FIGURE 1 Schematic representation of the reaction
to produce P5K6. In addition to the speciﬁc reaction of
the two b-subunit Cys-93 residues to produce P5K2,
an additional four to ﬁve lysine surface residues are
modiﬁed by thiolation, followed by the maleimide-
PEGylation reaction.
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P5K2, and P5K6 for the highest measured concentrations
(computed as ratios to the scattering at the lowest concen-
tration) are presented in Fig. 2 B. Although the highest
concentration of native Hb (31.5 mg/ml) exceeded those of
P5K2 and P5K6 (25 and 21 mg/ml, respectively), the
interference effect of Hb is relatively small compared to the
PEGylated samples. The average distance between Hb mol-
ecules computed from the maximum in the structure factor
is ;75 A˚, which is close to the diameter of the crystallo-
graphic model of oxyHb (70 A˚; PDB entry code 2DN1). The
maxima in the structure factors of P5K2 and especially P5K6
are much more pronounced and reveal larger interparticle
separations (;100 and 140 A˚, respectively). The strong re-
pulsive interactions thus can be attributed unambiguously to
the attached PEG chains.
Further analysis of the structure of the Hb constructs was
performed using the data extrapolated to inﬁnite dilution to
exclude the interference effects (Fig. 3 A). The scattering
pattern from Hb yields a radius of gyration Rg ¼ 23.7 6
0.3 A˚, in agreement with the value calculated from the
crystallographic model of oxyHb (23.5 A˚). Moreover, the
scattering computed from the latter model ﬁts the experi-
mental data well with x ¼ 1.4, whereas the ﬁt from deoxyHb
(PDB entry code 2DN2) is worse (x ¼ 1.8; the ﬁts are
displayed as dashed lines in Fig. 3 A). This indicates that the
PEGylated Hb core adopts the oxy, R-state conformation
under our experimental conditions. As expected, the scat-
tering patterns from P5K2 and P5K6 yield larger Rg values
(28.36 0.5 A˚ and 35.66 0.6 A˚, respectively) and cannot be
ﬁtted by the computed scattering from the oxyHb model
(x ¼ 3.9 and 5.0, respectively). Further, the computed vol-
umes of the hydrated particles are (1.056 0.05)3 105 A˚3 for
Hb, (1.20 6 0.05) 3 105 A˚3 for P5K2, and (1.50 6 0.10) 3
105 A˚3 for P5K6, reﬂecting the volume increase due to the
PEG chains. The contribution of the latter becomes even
more evident in the distance distribution functions displayed
in Fig. 3 B. The maximum particle diameter Dmax ¼ 70 6
5 A˚ of Hb coincides with that of the crystal structure of
oxyHb (27), whereas P5K2 and P5K6 yield Dmax ¼ 115 6
5 A˚ and Dmax ¼ 130 6 10 A˚, respectively. For interatomic
distances below 50 A˚, which largely reﬂect the internal
structure of Hb, the three p(r) functions nearly coincide,
indicating that the protein structure remains intact upon
PEGylation. This is further corroborated by the fact that
the three experimental scattering patterns from native and
PEGylated Hb neatly overlap at higher angles (scattering
vectors s . 0.2 A˚, i.e., resolution better than 30 A˚; see Fig. 2
A) and remain similar to the computed scattering from the
atomic model of oxyHb in this angular range. The p(r) func-
tions of the two PEGylated samples display decaying tails due
to the PEG contribution. Interestingly, both functions of P5K2
and P5K6 reveal a peak at the interatomic distance ;75 A˚
(indicated by an arrow in Fig. 3 B), just 5 A˚ beyond the
diameter of Hb, which indicates that a portion of PEG chains
is bound on the surface of Hb. However, a signiﬁcant amount
of PEG chains moves away from the surface, leading to a
noticeable increase in the particle size upon PEGylation.
Ab initio structure determination
The low-resolution structures of Hb, P5K2, and P5K6 were
further elucidated ab initio using the program GASBOR.
FIGURE 2 Scattered intensities of Hb at 5 g/l (pink) and 31 g/l (blue) and
of P5K6 at 5 g/l (green) and 21 g/l (red) (A). Structure factors of Hb (blue),
P5K2 (green), and P5K6 (red) (B).
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First, the shape of Hb was reconstructed in several indepen-
dent runs, without symmetry or by imposing P2 and P222
symmetry restrictions. All these reconstructions yielded
models that neatly ﬁt the experimental scattering from Hb
(x ¼ 1.05; Fig. 3 A), which are also consistent with the
crystallographic structure of oxyHb (see the overlap of the
typical GASBOR model in P222 symmetry with the PDB
entry 2DN1 in Fig. 4, A and B). The models for P5K2 and
P5K6 (ﬁts with x ¼ 1.2 and 1.3, respectively; Fig. 3 A)
resulted in elongated structures containing a core with the
shape similar to that of oxyHb with two protrusions at op-
posite poles, apparently representing the PEG chains (see
Fig. 4, C and D, for models generated in P222 symmetry).
Of great interest from this analysis, the core of PEG-Hb
appears to be more compact compared to that of unmodi-
ﬁed Hb.
An alternative model of the PEGylated Hb was built using
the multiphase ab initio program MONSA by simultaneous
ﬁtting of the three available data sets by a bead model
showing the three structural components (Hb, Hb plus two
PEG chains as in P5K2, and an additional four chains as in
P5K6). The typical model constructed using P222 symmetry
yields very good ﬁts to the scattering patterns after subtrac-
tion of the appropriate Porod constants (as described in
Materials and Methods) with x ¼1.2, 1.3, and 1.5 from Hb,
P5K2, and P5K6, respectively. The MONSA ﬁts are
displayed in Fig. 3 A (note that due to the constant subtrac-
tion, the computed patterns go below the raw experimental
data at higher angles). The model is shown in Fig. 5, A and C,
where the colored beads represent volumes occupied by the
different structural components. The shape of Hb (cyan
beads in panels A and C) is adequately reconstructed, with
results similar to those using GASBOR. In Fig. 5, B and D,
the Ca chains in oxyHb (PDB entry 2DN1) are positioned to
best match the Hb part of the model. The PEG chains display
elongated conﬁgurations, and the overall MONSA-generated
shapes are compatible with those from GASBOR (see Fig.
4). Note that in the MONSA model, the PEG chains of P5K2
appear to protrude to extremities of the model, such that the
apparent maximum size of the P5K2 model nearly matches
that of P5K6. The few beads of the P5K2 chains in the
MONSA model making up the larger distances however
make little contribution to the computed scattering, and their
presence may simply reﬂect the ﬂexibility of the PEG chains
in P5K2. The experimental value Dmax for P5K2 (115 A˚) is
clearly smaller than that of P5K6 (130 A˚), in agreement with
the GASBOR-generated models. Overall, the multiphase
bead MONSA modeling yields a lower resolution than
GASBOR but distinguishes between Hb and PEG chains and
provides direct evidence that PEG is found on the periphery
of the Hb volume, perhaps interacting with surface residues.
As seen from Fig. 5, B andD, some PEG beads also penetrate
into the Hb-occupied volume. Given the low resolution of
the model, it is of course impossible to discuss details of
localization of these PEG chains, but it appears conceivable
FIGURE 3 Processed experimental scattering data (from top to bottom:
Hb, P5K2, and P5K6), and the scattering calculated from the models. Solid
lines and open circles are the ﬁts by ab initio models from GASBOR and
MONSA, respectively; dashed lines are scattering patterns computed from
the crystallographic models of oxyHb or deoxyHb. The curves are displaced
along the abscissa axis for clarity (A). Distance distribution functions of Hb
(blue), P5K2 (green), and P5K6 (red); the arrow marks the maximum
appearing in the PEG-containing constructs at r ¼ 75 A˚ (B).
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that they may occupy the internal cavities between the Hb
subunits.
DISCUSSION
In this study, we present SAXS solution structures for Hb
and Hb conjugated with two or six to seven copies of 5-kD
PEG. This is the ﬁrst example of a 3D structural determi-
nation of a PEG-conjugated hemoglobin, albeit at a low
resolution. The most important ﬁndings from this study are:
i), PEG conjugation does not induce any gross distortion of
the tertiary structure of Hb (at this resolution), but its
quaternary structure appears compacted; ii), part of the PEG
chains enters into cavities between the Hb subunits, part
remains near the protein surface, and the rest protrudes away
from the surface; iii), PEGylation changes the spherical Hb
molecule into an elongated structure with either two or six
PEGs conjugated; iv), PEG conjugation leads to repulsion
FIGURE 4 Representative GASBOR models of Hb (A),
P5K2 (C), and P5K6 (D). Dark blue beads show the pro-
tein and/or PEG dummy residues, light gray beads rep-
resent the dummy waters imitating the solvation shell.
Structural alignment of the Hb model (shown as a transpar-
ent surface) to the crystal structure of oxyHb (shown as a
ribbon model) (B).
FIGURE 5 Low-resolution multiphase model of PEGy-
lated Hb constructed ab initio using the program MONSA.
Cyan beads belong to Hb, red beads belong to the two PEG
chains in P5K2, and yellow beads are the rest of the four to
ﬁve PEG chains in P5K6; bead radius, 2.5 A˚ (A and C). In
the right panel (B and D), the Ca chains in oxyHb (PDB
entry 2DN1) were positioned by Supcomb (24) to best
match the beads depicting the Hb volume (the latter are not
displayed for clarity). The Cys-b93 residues are shown in
the crystal structure in purple. Also in panels B and D, the
red beads were made larger to better see them; in panels A
and C, they are of equal size and thus masked by yellow
beads. The bottom view is rotated counterclockwise by 90
around the vertical axis.
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between the PEGylated Hb molecules caused by the PEG
layer that surrounds the protein Hb, which is manifested by a
marked concentration effect in the SAXS data.
The experimental scattering from Hb is well ﬁtted by
the calculated curve from the crystal structure of oxyHb,
whereas the deoxyHb crystal structure yields a worse ﬁt.
Both P5K2 and P5K6 are conjugated at Cys-b93 adjacent
to the proximal His-b92, which is the only residue in the
b-subunits of Hb directly coordinated to the heme iron. It
seems likely that the attachment of a 5-kD PEG causes local,
minor structural distortions of the b-subunit heme pocket
that are not detectable at this resolution (;12 A˚). This is
supported by studies of heme loss kinetics that are 5 times
higher for the b-subunit of P5K6 compared to nonconju-
gated Hb, whereas the a-subunits show similar kinetics to
Hb (8). Consistent with this interpretation, 1H NMR studies
of a PEG-conjugated Hb, which is similar in chemical struc-
ture to the P5K6 studied here, showed a shift in the proximal
histidine of the b- but not a-subunits (28). Moreover, resi-
dues in the vicinity of Cys-b93 are located in a conforma-
tionally plastic region that is directly linked to the allosteric
properties of Hb (29,30).
Modiﬁcation of Cys-b93 residues with N-ethyl maleimide
alone causes a loss in cooperativity, and this effect, along
with compaction of the quaternary structure, may explain the
apparent loss in cooperativity in Hemospan (5). Quaternary
movement could be restricted, giving rise to only partial
transition between R and T states or an intermediate quater-
nary structure. Such an effect has been considered previously
to interpret the kinetics of O2 binding to Hemospan (7).
Given that the wide-angle portions of scattering from Hb
and PEG-Hb coincide, signiﬁcant tertiary/secondary struc-
ture changes due to PEGylation can be excluded, and our
results thus point to a more compact quaternary structure of
the PEGylated protein. This can be explained by a partial
dehydration of the intersubunit interfaces caused by the PEG
chains, which are, rather unexpectedly, partially located in
the interior of the PEG-Hbs. The quaternary structure of
oxyHb creates a central cavity between the four subunits of
hemoglobin. The cavity can accommodate at least 80 water
molecules as shown in the high-resolution crystal structure
of oxyHb (27). Accordingly, the volume is sufﬁcient for
PEG to enter the intersubunit interface and displace water
molecules located in the interior of the tetramer. Moreover,
PEG is known to cause dehydration and is often used as a
cosolvent for protein crystallization. In conjunction with
displacement of water molecules located in the central cavi-
ty, a general dehydration may contribute to the compact
quaternary structure of PEG-Hbs. This conclusion is con-
sistent with molecular dynamic simulations that have shown
a correlation between extent of PEGylation and PEG-Hb
molecular volume, with a corresponding displacement of
water molecules from the Hb structure (31).
As the major part of PEG chains is located outside Hb, our
results agree with earlier studies showing that PEG is prefer-
entially excluded from proteins by steric exclusion (32).
Moreover, but in competition with exclusion forces, PEG has
been shown to interact with nonpolar protein surface resi-
dues (32), and interaction of 5-kD PEG has been reported
for hydrophobic clusters on the surface of cytochrome c (33).
The hydrophobicity score for Hb was calculated according to
Kyte and Doolittle (34) (Fig. 6), showing residue numbers
aligned with helical segments. A region of particular interest
in possible PEG-Hb interactions is over the relatively hy-
drophobic G-H helices at the a1b1 packing contacts between
dimers. Our models display surface interactions of PEG with
Hb, although the resolution is insufﬁcient to deﬁne the Hb
residues involved or their polarity. Analysis of SAXS spectra
recorded at a relatively high protein concentration shows a
clear concentration effect for both P5K2 and P5K6, whereas
this effect is nearly absent in nonconjugated Hb. As might be
expected, the concentration effect is more pronounced for
P5K6 than for P5K2, suggesting that the introduction of
additional PEG chains results in a better shielding of the Hb
molecule, also in agreement with molecular dynamics cal-
culations of theoretical PEG-conjugated Hbs (31).
Intuitively, one would expect the PEG-Hbs to have the
same shape as the nonPEGylated Hb, but here we show that
the shape of a PEGylated protein is not deﬁned by that of the
core protein. The nonspherical solution shape of the PEG-
Hbs was not anticipated and provides new information by
which to calculate PEG-Hb diffusion constants using the
Stokes-Einstein equation. We have reported simulations of
oxygen transport by cell-free Hbs, including PEG-Hb, where
Hb molecular diffusion was shown to be one critical factor
in overall oxygen transport (35). Although the conclusion
holds, that study used the simplifying assumption that the Hb
molecules were spherical. Since the SAXS solution structure
contradicts this assumption, correct molecular dimensions
can now be employed to provide more accurate simulations.
Further, although both P5K2 and P5K6 have similar shapes
and overall dimensions, the difference in the repulsive effect
FIGURE 6 Hydrophobicity plot for Hb (34). The hydrophobicity score is
shown for residue numbers aligned with subunit helical segments.
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of the particles in solution provides a highly critical property
that may explain some of the positive effects of PEGylated
Hbs in vivo. The generality of these observations can be
attributed to the attached PEG chains and suggests that the
concentration effect is a general consequence of PEG
conjugation. Accordingly, in vivo, one may hypothesize
that this effect not only prevents intermolecular interactions
between adjacent PEG-conjugated proteins but also between
conjugated and nonconjugated proteins or even cellular
structures.
Several general beneﬁts, such as increased intravascular
retention time, decreased immunogenicity, and improved
solubility, are frequently associated with the attachment of a
PEG polymer to a protein. For instance, attaching a 40-kDa
branched PEG polymer to interferon-b-1b markedly im-
proved its circulating half-life from 1.1 h for the nonconju-
gated protein to 9.4 h for the PEG-conjugated drug;moreover,
attachment of PEG dramatically decreased the immunoge-
nicity of the protein and the tendency for aggregation (4). The
ability of PEG-Hb to exclude other proteins or cells within
its excluded volume is particularly critical in the design of
oxygen therapeutics. Hemoglobin-based products are being
optimized to extend circulating time, while minimizing or
eliminating toxicity. This result is consistent with the ex-
tended circulatory half-life of Hemospan, which is ;20 h in
the absence of hemoglobinuria (14), compared to the very
rapid renal clearance of unmodiﬁed, cell-free Hb (36). Pro-
longation of Hemospan circulation time may arise if it does
not bind to the macrophage CD163 receptor, an Hb scavenger
that shows progressively decreasing binding of polymerized
Hbs with increasing size (37). Studies with Hemospan in this
system are underway. In addition, repulsion of PEG-Hb from
other immune cells may be critical to avoid inﬂammatory
responses. Prevailing theories about cell-free hemoglobin-
induced vasoconstriction are that the Hbmolecules come into
close approximation with endothelium (38) or extravasate
across the endothelium (39), either of which would make NO
scavenging more efﬁcient, thus leading to an increase in
vascular tone and negative side effects of hypertension and
decreased perfusion (40). It remains speculative at this point,
but the repulsive nature of the PEG modiﬁcation may reduce
its interactionwith the surface glycocalyx of endothelial cells;
thus the repulsive effect provides an explanation for the
lessened vasoactivity with Hemospan (10).
These new insights from this SAXS analysis can now be
used to design PEG-Hbs for maximal or optimal repulsion
effects and particle size and PEG conformations. Intermo-
lecular repulsive forces increase substantially with the total
mass of conjugated PEGs with the same polymer length (10
vs. ;30 kD for P5K2 versus P5K6), an effect that was not
predicted by changes in molecular shape and/or dimensions.
Thus, solution conformations of the conjugated PEGs, which
includes its interaction with Hb, other PEG polymers, and
surrounding water layers, must play a large role in the repul-
sion effect.
Effective PEG lengths are deﬁned by the Flory dimension,
RF, which is determined from the effective length of an
oxyethylene unit, a¼ 3.5 A˚ (41), and the number of units per
polymer, N (42–44):
RF ¼ aN3=5:
The relative dimensions of RF and the distance between
PEG grafting sites, DG, on a surface determine the secondary
structure of the grafted PEG polymer: for DG. RF, the PEG
polymer is able to fold in on itself over the grafted surface,
giving a ‘‘mushroom’’ conformation; forDG, RF, the PEGs
become extended due to steric interactions between PEG
chains to form a ‘‘brush’’ conformation; and at DG RF, the
PEGs are in a ‘‘mushroom-to-brush’’ transition phase (45).
For 5-kD PEG, N ¼ 113 and RF ; 60 A˚. Since the half-
maximal circumference DG on the Hb surface from one
Cys-b93 to the other on the symmetrically opposite side of
Hb is ;110 A˚, DG . RF, thus allowing a mushroomed
conformation of the grafted PEG polymers in P5K2. This is
reﬂected in the PEG features from the SAXS structure of
P5K2, showing an overall ellipsoidal shape with Dmax¼ 115
A˚. Calculation of the maximal diameter for P5K2 using
the Flory dimension for 5-kD PEG gives a molecule with
Dmax; 190 A˚ (i.e., Hb diameter¼ 70 A˚1 PEGs, 23 60 A˚),
thus providing an estimation for the mushroom conformation
of the PEG chains on P5K2 that fold to ;60% of their full
Flory dimensions.
The more highly PEG-coordinated P5K6 molecule con-
tains the two speciﬁc attachment sites (Cys-b93) and an
additional four to ﬁve more PEG grafted sites. The SAXS
solution structure implies that the PEG chains of P5K6 have
greater steric interaction to form an even more elongated
shape compared to P5K2 (Fig. 4). Using an approximation
that the PEG chains are evenly distributed over the surface of
Hb,DG is decreased to;55 A˚, andDG RF, thus suggesting
a more extended PEG conformation but still in a mushroom-
to-brush transition. Using the maximal Flory dimension
compared to the measured Dmax ¼ 130 A˚, the 5-kD PEG
chains on P5K6 appear to fold to ;70% of their full Flory
dimension, consistent with an increase in PEG extension in
P5K6 compared to P5K2 by steric constraints.
By direct determination of particle size by SAXS com-
bined with Flory analysis, we have predicted that P5K6 is in
a mushroom-brush transition and thus was not designed to
reach its maximal particle size when the conjugated PEGs
are fully extended. New PEG-Hb molecules can be engi-
neered for larger particles, such that DG , RF either by: 1),
creating a more highly conjugated Hb with more PEG
attachment sites, thus decreasing DG, or 2), increasing PEG
length, thus increasing RF. Doubling the size of PEG to 10
kD (i.e., P10Kx, where x is the number of conjugation sites),
increases RF to ;90 A˚, which we predict would provide
a mushroom conformation in P10K2 but would approach a
fuller brush conformation in P10K6. It is, however, unknown
how extending PEG polymer lengths alters steric interactions
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during the PEG-Hb chemical conjugation reaction, and so
new designs warrant experimental practice with reaction
ratios in conjunction with SAXS studies to verify the
mushroom-to-brush transition point.
SUMMARY
In summary, we have demonstrated that SAXS in conjunc-
tion with ab initio structure determination methods is a tech-
nique suitable for structural studies of PEGylated proteins.
Using this approach, we can conﬁrm that the overall tertiary
structure of Hb remains intact upon conjugation with two or
six to seven PEG chains, but its quaternary structure appears
to be compacted, presumably due to the dehydration of
the intersubunit interfaces. The reconstructed shapes of Hb,
P5K2, and P5K6 illustrate that the PEG chains interact with
the core Hb molecule and also protrude to form either a dual
mushroom (P5K2) or a dual mushroom-to-brush (P5K6)
conformation. SAXS measurements reveal two properties
critical for the pharmacodynamic development of PEG-Hbs
as oxygen therapeutics: 1), The repulsion effect growing
with the degree of PEGylation opens the way to use SAXS
for optimization of PEG lengths and sites of attachment to
the protein by maximizing the concentration effect. 2), The
transition point between PEG mushroom and brush confor-
mations is critical in determining overall particle size and
shape. A brush conformation would lead to larger molecular
dimensions, which in turn will affect the diffusion behavior
of the particle and perhaps its rate of clearance.
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